Sugi Predict

Sugi Predict / Compounds / SCHEMBL1424930

SCHEMBL1424930

SCHEMBL1424930

COc1cc(Cl)ncc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ ALDH1A1 P00352 4/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ DYRK1A Q13627 1/20 0.40
▸ HSP90AA1 P07900 2/20 0.39
▸ HSP90AB1 P08238 1/20 0.39
▸ RAB9A P51151 2/20 0.38
▸ POLB P06746 1/20 0.38
▸ PDE10A Q9Y233 1/20 0.37
▸ TAAR1 Q96RJ0 1/20 0.37
▸ DHFR P00374 1/20 0.37
▸ PGK1 P00558 1/20 0.37
▸ GSK3B P49841 1/20 0.37
▸ MAP4K2 Q12851 1/20 0.37
▸ PDGFRB P09619 1/20 0.37
▸ PDGFRA P16234 1/20 0.37
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30503613 1.00 NPC1 (0.43) NPC1GAAALDH1A1KDM4ESMN1; SMN2
SCHEMBL23912507 0.84 ALDH1A1 (0.47) NPC1ALDH1A1KDM4ESMN1; SMN2RAB9A
SCHEMBL20225783 0.82 NPC1 (0.43) NPC1GAAALDH1A1KDM4ESMN1; SMN2
SCHEMBL16200086 0.80 SLC6A2 (0.43) NPC1GAAALDH1A1KDM4ESMN1; SMN2
SCHEMBL29513500 0.80 GAA (0.42) NPC1GAAALDH1A1KDM4ESMN1; SMN2
SCHEMBL30013468 0.80 S1PR1 (0.42) NPC1ALDH1A1KDM4ESMN1; SMN2HSP90AA1
SCHEMBL25347088 0.80 GAA (0.42) NPC1GAAALDH1A1KDM4ESMN1; SMN2
SCHEMBL1425419 0.80 S1PR1 (0.42) NPC1ALDH1A1KDM4ESMN1; SMN2HSP90AA1
SCHEMBL18797516 0.78 GAA (0.41) NPC1GAAALDH1A1KDM4ESMN1; SMN2
SCHEMBL24816680 0.78 MAOB (0.42) NPC1ALDH1A1KDM4ESMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4217062-B1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-10-09 — — EP disclosed
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-06-27 — — US disclosed
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-10-31 — — US disclosed
EP-4217062-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN Pharmaceutica NV (BE) 2023-08-02 — — EP disclosed
CN-116323557-A Cyclobutylamide monoacylglycerol lipase modulators 詹森药业有限公司 2023-06-23 — — CN disclosed
US-11390618-B2 Inhibitors of cyclin-dependent kinases KINNATE BIOPHARMA INC. (US) 2022-07-19 — — US disclosed
US-11358958-B2 — — 2022-06-14 — — US disclosed
US-11358958-B2 — — 2022-06-14 — — US disclosed
WO-2022063784-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-03-31 — — WO disclosed
US-20220089538-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-03-24 — — US disclosed
US-20210130340-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES KINNATE BIOPHARMA INC. 2021-05-06 — — US disclosed
EP-3813819-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES Kinnate Biopharma Inc. (US) 2021-05-05 — — EP disclosed
CN-112638373-A Cyclin-dependent kinase inhibitors 金耐特生物制药公司 2021-04-09 — — CN disclosed
US-10894788-B2 Inhibitors of cyclin-dependent kinases KINNATE BIOPHARMA INC. (US) 2021-01-19 — — US disclosed
US-10894788-B2 Inhibitors of cyclin-dependent kinases KINNATE BIOPHARMA INC. (US) 2021-01-19 — — US disclosed
CN-106349234-A Aminopyrimidine derivatives as LRRK2 modulators 霍夫曼-拉罗奇有限公司 2017-01-25 — — CN disclosed
CN-102648198-B Pyridine derivatives as S1P1/EDG1 receptor modulators ACTELION PHARMACEUTICALS LTD 2015-04-01 — — CN disclosed
US-8598208-B2 Pyridine derivatives as S1P1/EDG1 receptor modulators ACTELION PHARMACEUTICALS LTD. (CH) 2013-12-03 — — US disclosed
US-20110212998-A1 PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-01 — — US disclosed
EP-2195311-B1 PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2011-03-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11358958-B2 — CDK2, CDK1, CDK6 NPC1 1972/4885GAA 1132/4885ALDH1A1 3425/4885
US-20210130340-A1 INHIBITORS OF CYCLIN-DEPENDENT KINASES CDK2, CCNK, CDK1 NPC1 2544/4885GAA 1676/4885ALDH1A1 3722/4885
US-10894788-B2 Inhibitors of cyclin-dependent kinases CDK2, CCNK, CDK1 NPC1 2544/4885GAA 1676/4885ALDH1A1 3722/4885
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP NPC1 1323/4885GAA 260/4885ALDH1A1 472/4885
US-20220089538-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP NPC1 1293/4885GAA 247/4885ALDH1A1 450/4885
US-11390618-B2 Inhibitors of cyclin-dependent kinases CDK2, CCNK, CDK1 NPC1 2544/4885GAA 1676/4885ALDH1A1 3722/4885
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators MGLL, LPL, PNLIP NPC1 1293/4885GAA 247/4885ALDH1A1 450/4885
US-20110212998-A1 PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS S1PR1, S1PR3, S1PR2 NPC1 1256/4885GAA 4126/4885ALDH1A1 1720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.